← All Halozyme Therapeutics, INC filings

Halozyme Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
HALO
Halozyme Therapeutics, INC
10-K: Halozyme Therapeutics Reports Strong 2024 Results, Driven by ENHANZE Royalties and Strategic Collaborations
Halozyme Therapeutics' 2024 results showcase significant revenue growth fueled by ENHANZE royalties and strategic partnerships, alongside key regulatory approvals and pipeline advancements.
NASDAQ
HALO
Halozyme Therapeutics, INC
10-K: Halozyme Therapeutics Reports 2023 Results, Outlines Key Milestones and Future Strategy
Halozyme Therapeutics' 2023 10-K filing highlights financial performance, strategic initiatives, and key risk factors, emphasizing growth through ENHANZE technology and auto-injector devices.